Anti-CD3 monoclonal antibody-ricin-chain-A conjugate

Drug Profile

Anti-CD3 monoclonal antibody-ricin-chain-A conjugate

Alternative Names: Anti-CD3F(ab')2-ricin-toxin-A-chain; SPV-T3a-ricin A

Latest Information Update: 10 Aug 1998

Price : $50

At a glance

  • Originator Nonindustrial source
  • Class Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Graft-versus-host disease

Most Recent Events

  • 10 Aug 1998 No-Development-Reported for Graft-versus-host disease in Netherlands (Unknown route)
  • 10 Aug 1998 No-Development-Reported for Graft-versus-host disease in USA (Unknown route)
  • 31 Dec 1996 A study has been added to the Transplant rejection pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top